Evidence map›Paper›PMID 35981002›Full record

ArticlePLoS neglected tropical diseases2022

Genome-wide analysis of Schistosoma mansoni reveals limited population structure and possible praziquantel drug selection pressure within Ugandan hot-spot communities.

Tushabe John Vianney, Duncan J Berger, Stephen R Doyle, Geetha Sankaranarayanan, Joel Serubanja, Prossy Kabuubi Nakawungu, Fred Besigye, Richard E Sanya, Nancy Holroyd, Fiona Allan and 4 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Tushabe John VianneyParasites and Microbes, Wellcome Sanger Institute, Hinxton, United Kingdom.
Duncan J BergerParasites and Microbes, Wellcome Sanger Institute, Hinxton, United Kingdom.
Stephen R DoyleParasites and Microbes, Wellcome Sanger Institute, Hinxton, United Kingdom.
Geetha SankaranarayananParasites and Microbes, Wellcome Sanger Institute, Hinxton, United Kingdom.
Joel SerubanjaImmunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
Prossy Kabuubi NakawunguImmunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
Fred BesigyeImmunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
Richard E SanyaImmunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
Nancy HolroydParasites and Microbes, Wellcome Sanger Institute, Hinxton, United Kingdom.
Fiona AllanDepartment of Life Sciences, Natural History Museum, London, United Kingdom.
Emily L WebbMRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Alison M ElliottImmunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
Matthew BerrimanParasites and Microbes, Wellcome Sanger Institute, Hinxton, United Kingdom.
James A CottonParasites and Microbes, Wellcome Sanger Institute, Hinxton, United Kingdom.ORCID 0000-0001-5475-3583
Wellcome Sanger Institute · GBUganda Virus Research Institute · UGLondon School of Hygiene & Tropical Medicine · GBAfrican Population and Health Research Center · KENatural History Museum · GB

Funding

Medical Research Council MC_UU_00027/5Medical Research Council MR/R010161/1Medical Research Council MR/T020733/1Wellcome Trust 095778Wellcome Trust 206194
6 · The paper itself

Abstract

Populations within schistosomiasis control areas, especially those in Africa, are recommended to receive regular mass drug administration (MDA) with praziquantel (PZQ) as the main strategy for controlling the disease. The impact of PZQ treatment on schistosome genetics remains poorly understood, and is limited by a lack of high-resolution genetic data on the population structure of parasites within these control areas. We generated whole-genome sequence data from 174 individual miracidia collected from both children and adults from fishing communities on islands in Lake Victoria in Uganda that had received either annual or quarterly MDA with PZQ over four years, including samples collected immediately before and four weeks after treatment. Genome variation within and between samples was characterised and we investigated genomic signatures of natural selection acting on these populations that could be due to PZQ treatment. The parasite population on these islands was more diverse than found in nearby villages on the lake shore. We saw little or no genetic differentiation between villages, or between the groups of villages with different treatment intensity, but slightly higher genetic diversity within the pre-treatment compared to post-treatment parasite populations. We identified classes of genes significantly enriched within regions of the genome with evidence of recent positive selection among post-treatment and intensively treated parasite populations. The differential selection observed in post-treatment and pre-treatment parasite populations could be linked to any reduced susceptibility of parasites to praziquantel treatment.

Indexed as

AnthelminticsSchistosomiasis mansoniAdultAnimalsChildHumansPharmaceutical PreparationsPraziquantelSchistosoma mansoniUgandaAnthelminticsPharmaceutical PreparationsPraziquantel

Identifiers

PMID35981002
PMCPMC9426917
OpenAlexW4292220074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.